Loading…
meRfi® Microbiome for Physicians: Concise, structured access to evidence-based gut microbiome literature — organized by disease, intervention, and mechanism, and continuously updated across gastroenterology, internal medicine, oncology, immunology, infectious disease, endocrinology, neurology, and nutrition medicine.
Every entry links back to the primary literature with full citations and study details, so you can move from a symptom to the underlying evidence in seconds during a consultation.
For gastroenterologists, internists, and primary care physicians, meRfi® Microbiome delivers practical, indication-specific recommendations (product, dose, duration) and separates robust evidence from marketing claims — faster than manual PubMed searches and general-purpose AI tools. A free trial without a credit card makes it easy to see the difference in your own practice.
… are interested in probiotics, prebiotics, and FMT as central tools to modulate the gut microbiota in IBD, IBS, C. difficile infection, and other gastrointestinal diseases. They discuss probiotics as an adjunctive therapeutic option (e.g., in ulcerative colitis, Crohn's disease, and irritable bowel syndrome) to correct dysbiosis, strengthen barrier function, and modulate inflammation. They use FMT mainly in recurrent CDI but are also interested in standardized, industrially produced microbiota-based products — currently mostly within clinical studies.
… use probiotics predominantly for antibiotic-associated symptoms and functional gastrointestinal disorders, but often assess their use with evidence-based skepticism. They view prebiotics primarily as a building block of a healthy, fiber-rich diet rather than as a pharmacological intervention. They know the principle of FMT and usually recommend it only in recurrent CDI, referring patients to specialized centers. They ask for practical, indication-specific recommendations (product, dose, duration) and a clear distinction between marketing claims and robust evidence.
… have a broad interest in probiotics, prebiotics, FMT, and the microbiome across GI, metabolic, immunological, and oncological conditions, but are cautious about broad prescriptions due to heterogeneous data and a lack of clear guidelines. They mainly use probiotics in IBS, IBD, C. difficile- or antibiotic-related diarrhea, liver cirrhosis, or susceptibility to infections. They regard prebiotics as a component of structured dietary concepts (e.g., in metabolic syndrome, NAFLD/MAFLD, functional constipation, IBS) but demand better data on dose, formulation, and long-term effects. They accept FMT primarily in recurrent CDI and partly in ulcerative colitis, refer to specialized centers, and remain critical regarding risks and regulatory issues. They recognize the potential of microbiome-related data for diagnostics and individualized therapy (e.g., in immune checkpoint inhibitor treatment), but critically reject commercial microbiome tests and exaggerated marketing claims. They wish for structured continuing education and practical, guideline-oriented recommendations.
The curated, continuously updated evidence base on the gut microbiota and related health topics provides the complete scientific context in a modern, encyclopedia-style format — including citations, study details, and structured summaries — and thus supports clinical decision-making, patient counseling, teaching, and research.
The integrated AI delivers comprehensive, consistent answers with fewer hallucinations, as well as contextualized, logically connected responses that can be used directly in patient consultations and for continuing and postgraduate education.
Here you will find a contextualized presentation of inflammatory diseases and the gut microbiota.
It covers the reduction of adverse events of cancer therapy and the improvement of its efficacy.
The most popular manipulators of the intestinal microbiota are introduced.
Axes may explain the influence of gut microbiota on extraintestinal diseases.
Strong and weak evidence.
Components of structured dietary concepts.
Mechanisms by which a resilient microbiota counteracts pathogens.
... and more